Find more items about these cancer types:

Breast

Zometa Lowers Breast Cancer Recurrence Risk

(00:04:17) ASCO, 2008 May 30, Mary Ellen Schneider

Dr. Michael Gnant is Professor of Surgery, Medical University of Vienna.

In a large trial of premenopausal patients with hormone-responsive breast cancer, adding zoledronic acid to tamoxifen or anastrozole decreased relapse risk by 36%.

See related videos to:
ASCO 2008, Clinical Trials

Related Links

View related Abstract No: LBA4 »
News Article: Zoledronic Acid Aids Disease-free Survival in Certain Breast Cancer Patients »
News Article: Zoledronic Acid Raises Disease-Free Survival in Premenopausal Breast Cancer »
News Article: Clodronate Ups Overall Survival in Metastatic Prostate Cancer »

NOT A MEMBER?

Registration is FREE

  • Up-to-date oncology news
  • Journal article summaries
  • Commentaries and interviews
  • Drug and interactions database
  • Chemotherapy regimens
  • Daily e-newsletters

 

Most Viewed Video

Expert Gives Overview of Gamechangers at 2011 ASCO Annual Meeting
Elsevier Global Medical News, 2011 Jun 4
OncologySTAT Video Network

Cancer Type

  • Bladder
  • Bone
  • Breast
  • Breast (ER-Positive)
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • Hodgkin's Lymphoma
  • Kidney (Renal Cell)
  • Leukemia
  • Liver and Bile Duct
  • Lung
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Diseases
  • Non-Hodgkin's Lymphoma
  • Pancreas
  • Pediatric Cancers
  • Prostate
  • Rare Cancers
  • Skin
  • Soft-Tissue Sarcoma
  • Stomach
  • Testicle
    • Forgot your password?
    Not a member? Free registration